Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
28
BHST Quote, Financials, Valuation and Earnings
Last price:
$6.3600
Seasonality move
:
95.03%
Day range:
$6.2700 - $6.8935
52-week range:
$4.7237 - $12.8000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
18.39x
Volume:
51.5K
Avg. volume:
92.3K
1-year change:
2.45%
Market cap:
$142.3M
Revenue:
$25.2M
EPS (TTM):
-$0.69
Analysts' Opinion
-
Consensus RatingBioHarvest Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.6667, BioHarvest Sciences, Inc. has an estimated upside of 117.62% from its current price of $6.2800.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.0000 representing 100% downside risk from its current price of $6.2800.
Fair Value
-
According to the consensus of 2 analysts, BioHarvest Sciences, Inc. has 117.62% upside to fair value with a price target of $13.6667 per share.
BHST vs. S&P 500
-
Over the past 5 trading days, BioHarvest Sciences, Inc. has underperformed the S&P 500 by -7.07% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioHarvest Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioHarvest Sciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioHarvest Sciences, Inc. reported revenues of $9.1M.
Earnings Growth
-
BioHarvest Sciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioHarvest Sciences, Inc. reported earnings per share of -$0.14.
Enterprise value:
151.1M
EV / Invested capital:
5.48x
Price / LTM sales:
3.33x
EV / EBIT:
--
EV / Revenue:
4.62x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-15.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$19.4M
Return On Assets:
-42.33%
Net Income Margin (TTM):
-36.33%
Return On Equity:
-733.31%
Return On Invested Capital:
-60.26%
Operating Margin:
-10.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.6M | $22.4M | $32.7M | $6.5M | $9.1M | |
| Gross Profit | $3.2M | $11.9M | $19.4M | $3.7M | $5.6M | |
| Operating Income | -$10M | -$7.9M | -$6.1M | -$2.1M | -$920K | |
| EBITDA | -$9.1M | -$6.7M | -$4.6M | -$1.8M | -$535K | |
| Diluted EPS | -$0.61 | -$1.20 | -$0.69 | -$0.16 | -$0.14 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.1M | $4.6M | $4.7M | $8M | $17.8M | |
| Total Assets | $12.4M | $9.6M | $10.6M | $25.8M | $35.2M | |
| Current Liabilities | $2.3M | $9.2M | $14.6M | $9.9M | $13.2M | |
| Total Liabilities | $8.5M | $13.1M | $18.3M | $21.7M | $27.5M | |
| Total Equity | $3.9M | -$3.5M | -$7.8M | $4.1M | $7.7M | |
| Total Debt | $6.1M | $3.8M | $3.7M | $11.8M | $16.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8M | -$7.3M | -$8M | -$1.8M | -$2.1M | |
| Cash From Investing | -$1.5M | -$2.9M | -$2.1M | -$470.3K | -$427.6K | |
| Cash From Financing | $8.8M | $11.3M | $18.5M | -$163.1K | $9.9M | |
| Free Cash Flow | -$9.5M | -$10M | -$10.1M | -$2.3M | -$2.5M | |
BHST
Sector
Market Cap
$142.3M
$131.7M
Price % of 52-Week High
49.06%
70.54%
Dividend Yield
0%
0%
Shareholder Yield
-3.96%
2.32%
1-Year Price Total Return
2.45%
-7.51%
Beta (5-Year)
1.176
0.259
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.5675
200-day SMA
Sell
Level
$7.4889
Bollinger Bands (100)
Sell
Level
6.9689 - 10.3889
Chaikin Money Flow
Buy
Level
265.8K
20-day SMA
Sell
Level
$6.8005
Relative Strength Index (RSI14)
Sell
Level
37.1540
ADX Line
Sell
Level
31.4183
Williams %R
Neutral
Level
-75.5102
50-day SMA
Sell
Level
$9.0801
MACD (12, 26)
Sell
Level
-0.7476
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
196.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.9072)
Sell
CA Score
(Annual)
Level (-5.3932)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.7787)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioHarvest Sciences, Inc. develops bio-cell growth platform technology. The firm engages in botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions. It offers nutraceutical health and wellness products, which includes dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients. The company was founded on April 19, 2013 and is headquartered in Vancouver, Canada.
Stock Forecast FAQ
In the current month, BHST has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHST average analyst price target in the past 3 months is $13.6667.
-
Where Will BioHarvest Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioHarvest Sciences, Inc. share price will rise to $13.6667 per share over the next 12 months.
-
What Do Analysts Say About BioHarvest Sciences, Inc.?
Analysts are divided on their view about BioHarvest Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioHarvest Sciences, Inc. is a Sell and believe this share price will drop from its current level to $12.0000.
-
What Is BioHarvest Sciences, Inc.'s Price Target?
The price target for BioHarvest Sciences, Inc. over the next 1-year time period is forecast to be $13.6667 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioHarvest Sciences, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BHST?
You can purchase shares of BioHarvest Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioHarvest Sciences, Inc. shares.
-
What Is The BioHarvest Sciences, Inc. Share Price Today?
BioHarvest Sciences, Inc. was last trading at $6.3600 per share. This represents the most recent stock quote for BioHarvest Sciences, Inc.. Yesterday, BioHarvest Sciences, Inc. closed at $6.2800 per share.
-
How To Buy BioHarvest Sciences, Inc. Stock Online?
In order to purchase BioHarvest Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BHST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BHST
Sector
P/E ratio
--
16.86x
PEG ratio
-0.02x
0.13x
P/B ratio
18.39x
1.49x
Price / LTM sales
3.33x
0.52x
Growth Metrics
BHST
Sector
Revenue growth
38.66%
3.13%
Earnings growth
7.03%
5.91%
Revenue (5-year growth)
158.55%
3.36%
Earnings forecast
-$0.12
$0.34
Profitability
BHST
Sector
Profitability FY 2024
$13.2M
$268.9M
Return on invested capital
-60.26%
4.48%
Return on assets
-42.33%
3.13%
Return on equity
-733.31%
7.78%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
BHST
Sector
Total cash
$11M
$89.9M
Short term investments
--
$32.9M
Total assets
$25M
$1.1B
Long term debt
$16.1M
$8.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
